A targeted, low-throughput compound screen in a Drosophila model of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD).

Alex Dyson, Megan Ryan, Shruti Garg, D Gareth Evans, Richard Baines

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A targeted, low-throughput compound screen in a Drosophila model of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD).'. Together they form a unique fingerprint.

Neuroscience